论文部分内容阅读
目的:研究辛伐他汀在低踝臂指数(ABI)患者治疗中的意义。方法:连续入选低ABI的入院患者,随访观察患者出院后3年内冠状动脉血运重建、急性心肌梗死及死亡等主要心血管不良事件(MACE)的发生情况,分析用药情况与MACE之间的关系。结果:随访发现,总计54例患者出现MACE,未服用辛伐他汀组较服用辛伐他汀组患者MACE明显增多(37.5%vs 22.6%,P<0.05)。结论:辛伐他汀可以改善低ABI患者的预后。
Objective: To study the significance of simvastatin in the treatment of patients with low ankle brachial index (ABI). Methods: The hospitalized patients with low ABI were enrolled in this study. The incidence of major adverse cardiac events (MACE) such as coronary revascularization, acute myocardial infarction and death within 3 years after discharge from the hospital were observed. The relationship between medication use and MACE . Results: A total of 54 patients showed MACE at follow-up. MACE was significantly increased in patients without simvastatin compared with patients receiving simvastatin (37.5% vs 22.6%, P <0.05). Conclusion: Simvastatin can improve the prognosis of patients with low ABI.